-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer
OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update
Seeking Alpha / 3 hours from now 1 Views
Comments